Impact of restarting warfarin therapy in renal disease anticoagulated patients with gastrointestinal hemorrhage

Renal Failure

Volumn 35, Issue 9, 2013, Pages 1228-1235

  Khalid, Fatima ^a   Qureshi, Waqas ^a   Qureshi, Sophia ^b   Alirhayim, Zaid ^a   Garikapati, Kiran ^a   Patsias, Iani ^a  

^a HENRY FORD HOSPITAL   (United States)

^b RAWALPINDI MEDICAL COLLEGE   (Pakistan)

Author keywords

Atrial fibrillation; Endoscopy; Gastrointestinal hemorrhage; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FRESH FROZEN PLASMA; NONSTEROID ANTIINFLAMMATORY AGENT; VITAMIN K GROUP; WARFARIN;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CHARLSON COMORBIDITY INDEX; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DRUG USE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENDER; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETREATMENT; RETROSPECTIVE STUDY; SURVIVAL; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; WARFARIN;

EID: 84884244379     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.819766     Document Type: Article

References (31)

1. Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: A systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest. 2012;142(6):1489-1498
2. Winkelmayer WC, Liu J, Patrick AR, Setoguchi S, Choudhry NK. Prevalence of atrial fibrillation and warfarin use in older patients receiving hemodialysis. J Nephrol. 2012;25:341-353
3. Nelson SE, Shroff GR, Li S, Herzog CA. Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in medicare patients. J Am Heart Assoc. 2012;1:e002097. doi: 10.1161/JAHA.112.002097
4. Schonburg M, Ziegelhoeffer T, Weinbrenner F, et al. Preexisting atrial fibrillation as predictor for late-Time mortality in patients with end-stage renal disease undergoing cardiac surgery-A multicenter study. Thoracic Cardiovascular Surgeon 2008;56:128-132
5. Laupacis A, Boysen G, Connolly S, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Internal Med. 1994;154(13):1449-1457
6. Collins AJ, Foley RN, Chavers B, et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis: Official J Natl Kidney Foundation. 2012;59:A7, e1-e420
7. Sood P, Kumar G, Nanchal R, et al. Chronic kidney disease and end-stage renal disease predict higher risk of mortality in patients with primary upper gastrointestinal bleeding. Am J Nephrol. 2012; 35:216-224
8. Coleman CI, Sobieraj DM, Winkler S, et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Practice. 2012;66:53-63
9. McCullough K, Sharma P, Ali T, et al. Measuring the population burden of chronic kidney disease: A systematic literature review of the estimated prevalence of impaired kidney function. Nephrol Dialysis Transplant: Official Publ Eur Dialysis Transplant Assoc-Eur Renal Assoc. 2012;27:1812-1821
10. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387-2394
11. Boland M, Murphy M, McDermott E. Acute-onset severe gastrointestinal tract hemorrhage in a postoperative patient taking rivaroxaban after total hip arthroplasty: A case report. J Med Case Rep. 2012;6:129
12. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-2870
13. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010;138:1093-1100
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Internal Med. 1999;130: 461-470
15. Genovesi S, Vincenti A, Rossi E, et al. Atrial fibrillation and morbidity and mortality in a cohort of long-Term hemodialysis patients. Am J Kidney Dis: Official J Natl Kidney Foundation. 2008;51:255-262
16. To AC, Yehia M, Collins JF. Atrial fibrillation in hemodialysis patients: Do the guidelines for anticoagulation apply? Nephrology (Carlton). 2007;12:441-447
17. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: Clinical features and associations with anticoagulant therapy. Kidney Intl. 2010;77:1098-1106
18. Nair M, Nayyar S, Rajagopal S, Balachander J, Kumar M. Results of radiofrequency ablation of permanent atrial fibrillation of42 years duration and left atrial size45 cm using 2-mm irrigated tip ablation catheter and targeting areas of complex fractionated atrial electrograms. Am J Cardiol. 2009;104:683-688
19. Pattakos G, Koch CG, Brizzio ME, et al. Outcome of patients who refuse transfusion after cardiac surgery: A natural experiment with severe blood conservation. Arch Internal Med. 2012;172: 1154-1160
20. Viviane A, Alan BN. Estimates of costs of hospital stay for variceal and nonvariceal upper gastrointestinal bleeding in the United States. Value Health: J Intl Soc Pharmacoecon Outcomes Res. 2008;11:1-3
21. Andrassy K, Ritz E. Uremia as a cause of bleeding. Am J Nephrol. 1985;5:313-319
22. Sagripanti A, Barsotti G. Bleeding and thrombosis in chronic uremia. Nephron 1997;75:125-139
23. Linne T. Prolonged bleeding time in non-uremic acute glomerulonephritis. Thrombosis Hemostasis 1979;42:1060-1061
24. Sagedal S, Hartmann A, Sundstrom K, Bjornsen S, Brosstad F. Anticoagulation intensity sufficient for hemodialysis does not prevent activation of coagulation and platelets. Nephrol Dialysis Transplant: Official Publ Eur Dialysis Transplant Assoc-Eur Renal Assoc. 2001;16:987-993
25. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20:2223-2233
26. Kussmaul W. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease. Ann Internal Med. 2012;157:302; author reply 3-4
27. Erdem Y, Haznedaroglu IC, Celik I, et al. Coagulation, fibrinolysis and fibrinolysis inhibitors in hemodialysis patients: Contribution of arteriovenous fistula. Nephrol Dialysis Transplant: Official Publ Eur Dialysis Transplant Assoc-Eur Renal Assoc. 1996;11: 1299-1305
28. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Intl. 1995;47:186-192
29. Knight TG, Ryan K, Schaefer CP, D'Sylva L, Durden ED. Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: The role of intravenous iron therapy. JMCP. 2010; 16:605-615
30. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook Jr. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: Meta-Analysis with estimates of risk and benefit. Ann Internal Med. 2005;143:241-250
31. Schreiber TL, Miller DH, Silvasi D, McNulty A, Zola BE. Superiority of warfarin over aspirin long term after thrombolytic therapy for acute myocardial infarction. Am Heart J. 1990;119: 1238-1244